ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,678, issued on July 1, was assigned to argenx BV (Ghent, Belgium).
"FcRn/HSA binding molecules and methods of use" was invented by Vladimir Bobkov (Ghent, Belgium), Karen Silence (Ghent, Belgium), Jolien Van Santbergen (Ghent, Belgium), Rene Bigirimana (Ghent, Belgium), Judith Baumeister (Ghent, Belgium), Johannes de Haard (Ghent, Belgium) and Christophe Blanchetot (Ghent, Belgium).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are binding molecules comprising a human neonatal Fc receptor (FcRn) binding molecule and at least one antigen-binding domain linked to the FcRn binding molecule. Polynucleotides, vectors, host cells, and method...